Yes and no. The bad press doesn't attract the uneducated investor. What probably has the biggest impact on share value not being realized is that many do not understand how good the BPAX cancer program really is. Libigel, Bio-t-Gel Elestrin, The Pill Plus are small potatoes to the real prize.
What I find interesting is the Price/Earnings ratio where BPAX is above the industry average by 272%. I attribute that to many companies doing cancer research having large expenses. If you look at what the Market Cap is on most companies doing strictly cancer research, they are trading at a much greater market value then BPAX. These companies for the most part have no diversity and are relying on one or two products in clinical trials, many in phase II. This proves to me that Cancer vaccine has not been priced into the market(yet).
This is where many are underestimating the business savy of BPAX Management. By getting 4 products Orphan Drug designation it opened the door to research opportunities at a lesser cost. This enhanced the work with John Hopkins University who is helping find partners and attracted additional funding. They have out-licenced to the university who will partner with other companies who want to try the GVAX in combination with one of their drugs. This is newest way to treat cancers. There are 17 cancer products presently in the BPAX pipeline using this process I see this number growing very quickly. It is like preparing a meal you have to try out different ingredients to see what works. BPAX will never have the cure for cancer treatment by itself. But no one else will either. But BPAX is poised to be an ingredient in many cancer cures. I believe the Lancet will be doing many more articles on GVAX as it is tried in different combinations. When these treatments are approved GVAX has a 30 % royalty established through the agreement with the university.
Bottom line, BPAX is able to move forward cancer research and eventually share in the spoils, while minimizing their expenses. This in addition to the fact that GVAX can be mass produced will translate into larger profits over the other cancer treatment products once approvals start coming in.
